SYDNEY, March 25, 2019 /PRNewswire/ -- Australian
oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA,
NASDAQ: KZIA) has been selected to present data from the Phase I
study of Cantrixil in ovarian cancer at the American Association
for Cancer Research (AACR) 2019 Annual Meeting.
AACR's Annual Meeting is one of the top-tier academic
conferences worldwide and brings together around 20,000
representatives from academia, industry, government and
advocacy organisations from across the globe. The meeting is being
held from 29 March to 3 April at the Georgia World Congress Center
in Atlanta, Georgia, USA.
Clinical Program Director, Daniel
Berg will be presenting on Kazia's Cantrixil Phase I in
ovarian cancer at the event on 1 April
2019. Mr Berg will present data from Part A of the
study -- the dose escalation component -- which completed
recruitment in October 2018.
TRX-E-002-1 (Cantrixil), is a third-generation benzopyran
molecule with activity against cancer stem cells and is being
developed to treat ovarian cancer. It was developed in Australia and initial preclinical studies were
conducted at Yale University. Cantrixil
was granted orphan designation for ovarian cancer by the US FDA in
April 2015.
The abstract presentation is entitled: Phase I Study of
Intraperitoneal TRX-E-002-1 in Patients with Persistent or
Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary
Peritoneal Cancer: Results of Dose-Escalation Phase.
The abstract has been authored by the trial's Principal
Investigators (PIs) - led by the two primary PIs in Australia and the US: Associate Professor
Jermaine Coward at the ICON Cancer
Care in Brisbane, Queensland and Dr Don
Dizon at the Lifespan Cancer Institute at Rhode Island
Hospital. The trial is being conducted across six sites in the US
and Australia as follows:
Country
|
State
|
Site
|
Principal
Investigator
|
US
|
Rhode
Island
|
Lifespan Cancer
Institute, Providence
|
Dr. Don
Dizon
|
US
|
Oklahoma
|
Stephenson Cancer
Center, Oklahoma City
|
Assoc. Prof. Kathleen
Moore
|
US
|
Texas
|
Mary Crowley Cancer Research Centre, Dallas
|
Dr. Minal
Barve
|
Australia
|
Queensland
|
ICON Cancer Care,
Brisbane
|
Assoc. Prof. Jermaine
Coward
|
Australia
|
New South
Wales
|
Westmead Hospital,
Sydney
|
Prof. Paul
Harnett
|
Australia
|
South
Australia
|
Flinders Medical
Centre, Adelaide
|
Dr. Ganessan
Kichenadasse
|
"The key objective with Part A of the Phase I study was to
assess the safety of the drug and find the right dose level to take
the study to the next stage. We are delighted to be presenting our
data at the AACR meeting and we look forward to discussing our
findings with clinicians and potential partners," said Cantrixil
Program Director Daniel Berg.
The presentation session details are as follows:
Session Title: Phase I Clinical Trials: Part 3
Date and Time: Monday April 1, 2019 1:00 PM - 5:00 PM
Location: Georgia World Congress Center, Exhibit Hall
B, Poster Section 16
Poster Board Number: 15
Permanent Abstract Number: CT091
Interested parties are encouraged to attend and can add the
session to their itinerary here:
https://www.abstractsonline.com/pp8/#!/6812/session/1315
Meanwhile, the link to the abstract is here:
https://www.abstractsonline.com/pp8/#!/6812/presentation/9899
The content of the abstract and presentation is embargoed until
the start of the conference when it will be available through the
above link and on the Kazia website.
***ENDS***
For more information on Kazia Therapeutics or Cantrixil, please
visit: www.kaziatherapeutics.com
Logo -
https://mma.prnewswire.com/media/766762/Kazia_Logo.jpg
View original
content:http://www.prnewswire.com/news-releases/kazia-to-present-on-cantrixil-at-american-association-for-cancer-research-aacr-2019-annual-meeting-300817517.html
SOURCE Kazia Therapeutics Ltd